Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04908189 · ClinicalTrials.gov registry record · Phase 3

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

A Phase 3 study of Psoriatic Arthritis, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
729
Enrollment target
20
Study locations

NCT04908189 is a Phase 3 study of Psoriatic Arthritis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 729 participants, below the 838-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04908189, a Phase 3 study of Psoriatic Arthritis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
729 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.

Conditions Studied

Psoriatic Arthritis

Interventions

  • OTHER Placebo
  • DRUG Deucravacitinib
  • DRUG Apremilast

Study Locations (20)

California

  • Local Institution - 0212 - Sacramento
  • Local Institution - 0188 - Whittier

New York

  • Local Institution - 0108 - New York
  • Local Institution - 0186 - Rochester

Texas

  • Local Institution - 0167 - Lubbock
  • Local Institution - 0070 - Mesquite

Alabama

  • Local Institution - 0149 - Mountain Brook

Illinois

  • Local Institution - 0192 - Skokie

Kentucky

  • Local Institution - 0203 - Hopkinsville

Louisiana

  • Local Institution - 0195 - Baton Rouge

Maryland

  • Local Institution - 0169 - Cumberland

Trial Details

FieldValue
Enrollment Target 729 participants
Start Date 2021-07-15
Est. Completion 2026-11-12
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04908189

The ClinicalTrials.gov registry entry for NCT04908189 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 729 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 838-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (13% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04908189 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT04908189 about?

NCT04908189 is a clinical study titled "A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment". The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will...

What is the current status of trial NCT04908189?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 729 participants. The study started on 2021-07-15. Estimated completion is 2026-11-12.

What conditions does trial NCT04908189 study?

This clinical trial studies the following conditions: Psoriatic Arthritis.

What interventions are being tested in trial NCT04908189?

The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG), Apremilast (DRUG).

Who is sponsoring clinical trial NCT04908189?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04908189 being conducted?

This trial has 20 study locations across Alabama, California, Illinois, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Psoriatic Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Psoriatic Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.